Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

Peking Union Medical College Hospital22 enrolled

Overview

The purpose of this prospective study is to determine the efficacy and safety of Rituximab plus Bortezomib in patients with newly diagnosed acquired hemophilia A.

This is a prospective, single-arm, open-label clinical trial to evaluate the efficacy and safety the regimen of Bortezomib with rituximab as first-line treatment to eradicate anti-factor VIII antibodies in newly diagnosed acquired hemophilia A. All of enrolled patients in this study will be injected Bortezomib plus rituximab. This study will be performed for about 2 years and approximately 22 patients will be enrolled in our insititution. After obtaining the written informed consent from the patients, the information of demographic and medical history will be collected and laboratory tests will be performed. Patients who meet the inclusion/exclusion criteria will be received the regimens: Bortezomib (1.3mg/m2 d1,4,8,11) with rituximab (375mg/m2 for one dose). The information of adverse events will be collected. In case that the evaluation of treatment response might be performed in regular clinical practice, those data will also be collected as well.

Study Type

INTERVENTIONAL

Allocation

Purpose

TREATMENT

Masking

NONE

Enrollment

Conditions

Acquired Hemophilia A

Interventions

BortezomibDRUG

Bortezomib intravenously 1.3mg/m2 d1,4,8,11 for 4 doses

RituximabDRUG

rituximab intravenously 500 mg for one dose

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: 1. Must be ≥ 18 years; 2. Understand and voluntarily sign an ICD prior to any study related assessments/procedures are conducted; 3. Diagnosis of acquired hemophilia A； 4. acute bleeding episodes(≥once). Exclusion Criteria: 1. Uncontrolled systemic infection; 2. Allergy to rituximab; 3. Positive for Lupus anticoagulant; 4. Life expectancy \< 3 months; 5. Pregnant and breastfeeding women; 6. Neuropathy\>Grade 1; 7. Positive for Hepatitis B surface antigen or hepatitis C antibody or human immunodeficiency virus（HIV）antibody; 8. Patients with poor compliance； 9. Patient who is considered by the investigator not suitable for clinical study.

Locations (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, China

RECRUITING

Outcomes

Primary Outcomes

The time to attain first complete remission (CR)

Complete remission defined as titer FVIII inhibitor lower than 0.6 Bethesda unit, factor VIII level\> 50% and no bleeding events without bypass treatments for 24 hours

Time frame: Last day of the treatment regimen (up to 3 months)

Secondary Outcomes

The time to durable treatment response

The time to durable treatment response was defined as the time from date of achieving CR until the date of relapse or date of death from any cause（whichever came first）

Time frame: During 24 month

Adverse events

Include major bleeding, infection, nerve toxicity, and so on.

Time frame: During 24 month

Overall survival

Overall survival was defined as the time from date of first diagnosis until the date of death from any cause，and death from any cause will be recorded.

Time frame: During 24 month

Central Contacts

Huacong Cai

CONTACT

01069158271 caihc@pumch.cn

Tienan Zhu

CONTACT

01069158271 zhutn@pumch.cn

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.